Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
ETNB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.16 - $11.84
Previous Close$6.59
Volume1.55M
Average Volume (3M)2.12M
Market Cap
$1.01B
Enterprise Value$504.37M
Total Cash (Recent Filing)$126.06M
Total Debt (Recent Filing)$37.55M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 07, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.43
Shares Outstanding145,984,180
10 Day Avg. Volume1,374,389
30 Day Avg. Volume2,121,173
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.40
Forecast
1Y Price Target
$23.78Price Target Upside242.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
89bio News
PremiumCompany Announcements
89bio Updates on Pegozafermin Clinical Progress
PremiumCompany Announcements
89Bio Inc. Faces Financial Risks Amid Market Challenges for Approved Products
PremiumCompany Announcements
89bio Inc. Advances Clinical Trials Amid Financial Losses
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPhase 3 NASH timelines remain on track, with significant future revenue opportunities projected for fibrotic and cirrhotic NASH.
Regulatory ApprovalPlans for accelerated and conditional approval in the U.S. and Europe for pegozafermin based on positive data from the ENLIGHTEN trials indicate potential future success.
Study ResultsPositive results from the earlier Phase 2 ENTRIGUE study showed impressive reductions in triglycerides, boosting confidence in pegozafermin's effectiveness for SHTG.
Bears Say
Clinical Trial DelaysThe decision to delay the data readout for the ENTRUST study was made following discussions with the FDA to reduce potential bias, not due to any unexpected safety or efficacy findings.
CompetitionPotential implications on pegozafermin’s regulatory pathway, physician prescribing, and access/reimbursement due to strong launch of a competitor's product.
Regulatory ChallengesA second pivotal trial in SHTG will be required for approval, potentially delaying the BLA filing process.
---
Ownership Overview
15.03% Insiders
11.48% Mutual Funds
0.61% Other Institutional Investors
61.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $4.16 and its highest was $11.84 in the past 12 months.
What is 89bio’s market cap?
89bio’s market cap is $1.01B.
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is May 07, 2025 which is in 10 days.
How were 89bio’s earnings last quarter?
89bio released its earnings results on Feb 27, 2025. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.752 by -$0.268.
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate is -0.51.
How many shares outstanding does 89bio have?
89bio has 145,984,180 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
89bio reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.752. Following the earnings report the stock price went down -0.966%.
Which hedge fund is a major shareholder of 89bio?
Currently, no hedge funds are holding shares in ETNB
---
89bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.78 (242.65% Upside)
$23.78 (242.65% Upside)
Blogger Sentiment
Bullish
ETNB Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 341.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.87%
12-Months-Change
Fundamentals
Return on Equity
-78.34%
Trailing 12-Months
Asset Growth
-19.72%
Trailing 12-Months
Company Description
89bio
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
---
ETNB Stock 12 Month Forecast
Average Price Target
$23.78
▲(242.65% Upside)
Technical Analysis
Spyre Therapeutics
―
Arcus Biosciences
―
Vir Biotechnology
―
Enliven Therapeutics
―
Mineralys Therapeutics, Inc.
―
Best Analysts Covering ETNB
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+78.26%
reiterated a buy rating 12 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +78.26% per trade.
---